drugset
drugset / Trial / NCT02930954

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

NCT02930954 ↗

Phase 2 Unknown 180 enrolled Caicun Zhou
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of combination of gefitinib and doublet chemotherapy or antiangiogenesis in advanced non-small cell lung cancer patients with EGFR activating mutation, accompanied with Bim deletion or low activating EGFR mutation abundance.

Timeline

Start
2016-11
Primary completion
2018-12
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Subject Carboplatin Small molecule — Intravenous
Subject Gefitinib Small molecule 250 mg Oral
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma